Search results
Results from the WOW.Com Content Network
Xeris Biopharma (NASDAQ:XERS) stock is rallying after the drug maker announced that its Recorlev drug had been approved by the U.S. Food and Drug Administration for certain patients with Cushing ...
Get breaking Business News and the latest corporate happenings from AOL. ... -U.S. private equity firm Bain Capital is set to raise its offer price for Japan's Fuji Soft to 9,600 yen ($63.35) per ...
But once housing prices sky-rocketed—his own home is worth about four times what he paid for it—that plan dissipated. Don bought his home when he was earning $14 per hour; that just isn't ...
For premium support please call: 800-290-4726 more ways to reach us
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Jan. 2023, I wrote about my 10 top stocks to buy for the new year. I ended up pretty proud of my list because if you'd invested $1,000 in each of the 10 stocks the day the article was published ...
For premium support please call: 800-290-4726 more ways to reach us
News. Science & Tech. Shopping. Sports. Weather. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Sign in. Mail. 24/7 Help. For premium support please call: